about
sameAs
Potential of functional MRI as a biomarker in early Alzheimer's diseaseBuilding a roadmap for developing combination therapies for Alzheimer's diseaseHierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex.Research priorities to reduce the global burden of dementia by 2025.Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trialsThe role of neuroimaging in elucidating delirium pathophysiology.Functional MRI studies of associative encoding in normal aging, mild cognitive impairment, and Alzheimer's disease.Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease.Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.Functional MRI detection of pharmacologically induced memory impairment.Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.The evolution of preclinical Alzheimer's disease: implications for prevention trials.Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer diseasePutting names to faces: successful encoding of associative memories activates the anterior hippocampal formationDevelopment of a process to disclose amyloid imaging results to cognitively normal older adult research participantsHippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults.Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans.Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer diseaseAmyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trialsSteps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease.Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.Tau positron emission tomographic imaging in aging and early Alzheimer diseaseReliability of functional magnetic resonance imaging associative encoding memory paradigms in non-demented elderly adults.Assessment of cognition in early dementia.Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit.The ADNI Publication Policy: commensurate recognition of critical contributors who are not authorsIn vivo characterization of the early states of the amyloid-beta network.In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain.Early risk assessment for Alzheimer's disease.A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease.Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective reviewBiomarkers of Alzheimer disease: current and future applications to diagnostic criteria.Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis.Charting a path toward combination therapy for Alzheimer's disease.Defeating Alzheimer's disease and other dementias: a priority for European science and society.Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.Challenges, solutions, and recommendations for Alzheimer's disease combination therapy.Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls.Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.Implementation of subjective cognitive decline criteria in research studies.
P50
Q26864734-3F1392FB-FBAC-441E-8A84-1E3AF404BF8EQ28611100-A0E40585-57B9-4645-8DFB-5519962E1D94Q30100986-097DFEE5-E257-4961-830D-43C9A51F2D50Q30244419-C1C7F18C-8C54-4E38-9125-54B00DEFB4F8Q31093236-54D9F7AF-335D-4ECF-9702-7A988936A4E9Q31094049-DB8B1188-C3EC-46D7-9192-3F988ABA811FQ31108283-B5F6A9CA-8C5D-4BF8-84B5-0E23FE43E763Q33681922-F87162A0-AD36-4827-804C-B43D7461034EQ33777535-FC045F12-FAEC-42F9-88E2-F51FF27442FAQ33898082-C33E9BF9-B429-4367-8398-C724C849AB0BQ34157492-B81BCF8D-823F-4DD6-80E6-0EDA6C3D215FQ34849048-BC112F04-C8B6-42BA-98BA-7BAE7F41BF94Q35169132-F14BE2AE-BE29-4A47-A646-A931471F8902Q35593109-AAFB083D-FD7A-4334-A9AE-A8185FF8E227Q35595661-E3244F13-D1FE-442B-A91C-8801A795AD81Q35787932-90A75FB3-8D95-48D9-AE32-506B3F449303Q35844926-83A3B45B-FBCE-4812-8AC7-345D723390BAQ36005633-029851C8-2AF7-4FC2-B6EE-EFE99F913939Q36005648-8CFB0040-4238-4E7C-956A-1FE9FFF7B8C8Q36093127-19BEDE59-127C-45AE-A365-B914DFE90842Q36276506-D1965212-02CE-4A58-8C35-96C596A4D010Q36535275-7009267C-CF08-490C-8F16-B25FFB2DDFD6Q36551535-9BA8C130-7DF8-49FA-B2A5-D259548F7E48Q36733293-2950ABAE-19C5-4F15-B126-C7807D964C7CQ36885357-C0A40CAF-BBFC-4BBA-9982-9DBE74032FFBQ36914046-E007C3F7-588D-44AA-BA60-489680ACC588Q36953870-CCE6E58F-5032-482E-B6C5-634A45AC28A3Q37096041-8DA38A4F-BAD5-46D3-A5D2-BEE61B263D3BQ37425804-CDA3419E-23AD-409C-AEEB-AAA67737728AQ37590389-8B659D89-D689-42FA-8090-3FA473F7C2B7Q37689697-F2E7F3CF-CC5F-4073-BE10-9F43B1BA4B74Q38096218-482130F8-0ABB-4216-B9E9-1E863D702E1CQ38220107-3CB494A9-3980-4937-B803-264A9B8BCAA7Q38300738-864A4D8D-0B17-4282-96A9-4AB5176BF568Q38778638-53CF6554-C132-4750-B769-16890004C20BQ38877710-5BEFF6AD-CC22-42EB-ACDC-50C3ACC00E07Q38889740-FB05AF76-E523-49A1-9D1D-B68B7EB217B9Q39028745-09E5F0A6-A822-4609-AE46-CE362EE1C544Q39365272-62941E32-D143-4BB1-96BA-3A61CFCB6B6AQ40483941-C93ED2F1-4643-43F3-8AAD-C1ABE878E842
P50
description
neurologist
@en
neuroloog
@nl
name
Reisa Sperling
@ast
Reisa Sperling
@en
Reisa Sperling
@es
Reisa Sperling
@nl
Reisa Sperling
@sq
type
label
Reisa Sperling
@ast
Reisa Sperling
@en
Reisa Sperling
@es
Reisa Sperling
@nl
Reisa Sperling
@sq
altLabel
R A Sperling
@en
R Sperling
@en
R. A. Sperling
@en
R. Sperling
@en
Reisa A Sperling
@en
Reisa A. Sperling
@en
Sperling R
@en
Sperling R. A.
@en
Sperling R.
@en
Sperling RA
@en
prefLabel
Reisa Sperling
@ast
Reisa Sperling
@en
Reisa Sperling
@es
Reisa Sperling
@nl
Reisa Sperling
@sq
P244
P1153
7101961665
P166
P21
P214
910148705737737080003
P244
no2007044817
P31
P7859
lccn-no2007044817
viaf-910148705737737080003